Gregg Alton serves as the CEO of Gilead Sciences, Inc. He took on the role temporarily in 2019 after being the Chief Patient Officer. Gregg has been with Gilead for over 20 years, leading important decisions and strategies to enhance...

Gregg Alton serves as the CEO of Gilead Sciences, Inc. He took on the role temporarily in 2019 after being the Chief Patient Officer. Gregg has been with Gilead for over 20 years, leading important decisions and strategies to enhance patient access to medicines worldwide. A Stanford Law School graduate, he has a strong legal background and has held key positions in medical affairs and corporate strategy at Gilead. In recent years, his stock holdings have fluctuated significantly, peaking at over $6 million, showcasing his personal investment in the company's performance. Interestingly, he did not receive a traditional salary in 2019, which reflects Gilead's focus on aligning compensation with company success. Instead, he earned bonuses tied to the company's performance metrics, truly committing to Gilead's vision of making life-saving treatments accessible to all.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Gilead Sciences CEOs

G

Gregg Alton

Ex-CEO of Gilead Sciences

Education

J.D. from Stanford Law School

Field of Expertise

Legal & Compliance - Legal

Sector of Economy

Healthcare

Born

June 1, 1966 - 58 years ago

CEO of Gilead Sciences for

0 years 2 months (Jan 2019 - Mar 2019)

Previous Experience

General Counsel and Chief Patient Officer at Gilead Sciences

Rivals

Competitors/colleagues of Gregg Alton

P

Albert Bourla

CEO of Pfizer

2023 Compensation

Stock

$0.00

Salary

$1.79M

Bonus

$0.00

Other

$2.26M

Total Holdings

$18.38M

M

Robert M. Davis

CEO of Merck & Co.

2023 Compensation

Stock

$17.72M

Salary

$1.60M

Bonus

$0.00

Other

$386.15K

Total Holdings

$5.80M

M

Stéphane Bancel

CEO of Moderna

2023 Compensation

Stock

$0.00

Salary

$1.58M

Bonus

$1.91M

Other

$1.07M

Total Holdings

$491.74M

V

Reshma Kewalramani

CEO of Vertex Pharmaceuticals

2022 Compensation

Stock

$10.64M

Salary

$1.40M

Bonus

$3.78M

Other

$43.06K

Total Holdings

$54.25M

V

Marianne De Backer, MSc, Ph.D., MBA

CEO of Vir Biotechnology, Inc.

2023 Compensation

Stock

$5.80M

Salary

$675.00K

Bonus

$855.36K

Other

$437.18K

Total Holdings

$5.17M

L

John L. Higgins

CEO of Ligand Pharmaceuticals

2022 Compensation

Stock

$0.00

Salary

$730.46K

Bonus

$0.00

Other

$0.00

Total Holdings

$48.52M

Holdings

See how much did Gregg Alton make over time.

Gregg Alton's stock holdings in Gilead Sciences have seen significant changes over the years. He owned around 58,046 shares, valued at over $6 million in late 2023. This substantial amount signals a solid commitment to the company's future. The peak...

Gregg Alton's stock holdings in Gilead Sciences have seen significant changes over the years. He owned around 58,046 shares, valued at over $6 million in late 2023. This substantial amount signals a solid commitment to the company's future. The peak value of his holdings showcases his confidence in Gilead's strategy and vision. Throughout his career, Alton has seen the value of his shares fluctuate due to changes in market conditions and company performance, providing a measure of how Gilead is being perceived by the market. His equity in the company has always been significant, indicating he has put a lot of his personal wealth at stake with the company's performance.

Mar 18, 2025

G

shares

GILD @ $110.23

Total Stock Sold

$139.42M

GILD

$139.42M

2,782,435 GILD shares

What if they kept their stock?

If Gregg Alton didn't sell their stock, today they would have:
Extra GILD2,782,435 shares worth $204.54M.
This is 46.7% and $65.11M more than what they got when they sold the stock.

Charitable Transactions

GILD

3,430 shares

GILD

Recent Charitable Transactions

GILD

1,430 shares

GILD

Feb 21, 2017

Charity

GILD

1,000 shares

GILD

Dec 22, 2014

Charity

GILD

1,000 shares

GILD

Aug 30, 2013

Charity

Insider Trading

See recent insider trades of Gregg Alton.

GILD

$18.96K

GILD at $57.45/share

Feb 15, 2019

Received

GILD

19,151 shares

GILD

Feb 6, 2019

Received

GILD

$1.97M

GILD at $78.66/share

Mar 1, 2018

Sale

GILD

$422.55K

GILD at $20.78/share

Feb 15, 2018

Received

GILD

$1.18M

GILD at $81.54/share

Feb 20, 2018

Sale

GILD

$2.09M

GILD at $83.47/share

Feb 1, 2018

Sale

GILD

$2.37M

GILD at $79.00/share

Jan 11, 2018

Sale

GILD

$1.10M

GILD at $73.40/share

Jan 2, 2018

Sale

GILD

$1.12M

GILD at $74.83/share

Dec 1, 2017

Sale

GILD

$1.13M

GILD at $75.11/share

Nov 1, 2017

Sale

Compensation History

See how much did Gregg Alton make over time.

In 2019, Gregg Alton's compensation reflected Gilead's pay-for-performance philosophy. He did not take home a traditional salary, meaning he was more invested in the company's success than in his paycheck. His total compensation structure was designed to align his earnings with the company's performance metrics rather than offering a stable salary. Bonuses were directly tied to achieving specific corporate targets, indicating a system where rewards are earned based on Gilead's achievements in advancing healthcare and providing patient access to their medicines. This approach signals a strong commitment to ensuring the well-being of the company and its stakeholders rather than just short-term financial gains.

Year

2019

Total Compensation

$0.00

Salary

$0.00

Board Justification

The compensation philosophy emphasizes pay-for-performance, aligning CEO compensation closely with market median pay and performance-based compensation.

Bonus

$0.00

Board Justification

The annual bonus plan is contingent upon performance in a number of pre-established categories including pipeline and product objectives, financial criteria, and organizational goals, but specific amounts for 2019 are not detailed in the provided text.

Other

$0.00

Board Justification

No specific details on other compensation for 2019 are provided in the text.

Restricted Stock

$0.00(0 N/A)

Board Justification

No specific details on vested stock for 2019 are provided in the text.

Performance Metrics

The CEO's bonus is tied entirely to corporate objectives, with annual pay reflecting a significant emphasis on performance-based compensation.

Other Gilead Sciences CEOs

Here are other CEOs of Gilead Sciences

John F. Milligan

Ex-CEO of Gilead Sciences

March 2016 - December 2018

Daniel O'Day

CEO of Gilead Sciences

March 2019 - Present